शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
APLLTDNSEAlembic Pharmaceuticals Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 5 Feb, 2026 · 14:00 IST

Alembic Pharma Q3 FY26: Revenue up 11%, PAT at Rs 133 cr

Exceptional ItemEbitda Margin ExpansionResults View source PDFExplain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.4%Reaction day
₹795.75
prior close
₹809.20
announcement price
In-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.0%+2.4% vs market
Pharmaceuticals peers, median of 157sector-0.5%+1.9% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.6
10m
+0.1
15m
+0.0
30m
+0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.4-1.0+2.4-0.5+1.9
Next day
-0.5-1.8+1.3-1.2+0.7
2d
+0.0+0.8-0.7+0.6-0.5
3d
+0.5+1.8-1.2+1.0-0.5
4d
+0.0+1.2-1.2+0.9-0.9
5d
-0.6+0.7-1.3+0.1-0.7
1w
-3.5-1.5-2.0-1.4-2.1
15d
-8.2-2.5-5.7-2.9-5.3
1m
-11.8-7.2-4.6-5.0-6.7
2m
-17.4-8.9-8.6-7.3-10.1
3m
-3.2+5.5-8.7+0.4-3.6
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharma posted Q3 FY26 consolidated revenue of Rs 1,876 cr, up 10.8% YoY. 9M revenue grew 12% to Rs 5,497 cr. Q3 PAT was Rs 133 cr, down 4% YoY, but 9M PAT rose 11% to Rs 472 cr. An exceptional charge of Rs 42 cr from new Labour Codes hit Q3 profits. Auditor is now KKC and Associates (previously KC Mehta). Board appointed Rajkumar Baheti as Non-Executive Director from April 2026.

Likely market impact

Q3 PAT dipped on one-time Labour Code charge; underlying business grew in double digits. New board role and auditor change noted.